Ridgeback Capital Reports New 7.6% Stake in Replimune Group, Inc.

On May 21, 2026, Ridgeback Capital Investments L.P., along with its affiliates Ridgeback Capital Investments LLC and Ridgeback Capital Management LLC, filed a Schedule 13G reporting a new 7.6% ownership stake in Replimune Group, Inc. (REPL). The reporting persons collectively hold 6,252,651 shares of common stock. The filing indicates that Ridgeback Capital Investments LLC serves as the general partner of Ridgeback Capital Investments L.P., while Ridgeback Capital Management LLC, controlled by Wayne Holman, maintains investment and voting power over the shares via an investment management agreement. The acquisition was triggered by an event on May 14, 2026. The reporting persons have certified that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This filing establishes Ridgeback Capital as a significant institutional shareholder in the biotechnology company, which is headquartered in Woburn, Massachusetts.